CoChat

Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis

Open access
Ryan, Paul M., Seltzer, Sean, Hayward, Nathaniel E., Rodriguez, David Avelar, Sless, Ryan T., Hawkes, Colin P. · 2021 · The Journal of Pediatrics
Cited by 111

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Objectives To determine the weight, body mass index (BMI), cardiometabolic, and gastrointestinal effects of glucagon-like peptide-1 (GLP-1) receptor agonists in children with obesity. Study design Web of Science, PubMed/MEDLINE, and Scopus databases from 01/01/1994-01/01/2021 for randomized control trials examining the weight, BMI, cardiometabolic, or gastrointestinal effects of GLP-1 receptor agonists in children and adolescents with obesity. Data were extracted by 2 independent surveyors and a random effects model was applied to meta-analyze generic inverse variance outcomes. Primary outcomes were related to weight and cardiometabolic profile, and secondary outcomes of interest were gastrointestinal-related treatment-emergent adverse events. Results Nine studies involving 574 participants were identified, of which 3 involved exenatide and 6 involved liraglutide. GLP-1 receptor agonists use caused a modest reduction in body weight (mean difference [MD] -1.50 [-2.50,-0.50] kg, I 2 64%), BMI (MD -1.24 [-1.71,-0.77] kg/m 2 , I 2 0%), and BMI z score (MD -0.14 [-0.23,-0.06], I 2 43%). Glycemic control was improved in children with proven insulin resistance (glycated hemoglobin A1c MD -1.05 [-1.93,-0.18] %, I 2 76%). Although no lipid profile improvements were noted, a modest decrease in systolic blood pressure was detected (MD -2.30 [-4.11,-0.49] mm Hg; I 2 0%). Finally, analysis of gastrointestinal-related treatment-emergent adverse events revealed an increased risk of nausea (risk ratio 2.11 [1.44, 3.09]; I 2 0%), without significant increases in other gastrointestinal symptoms. Conclusions This meta-analysis indicates that GLP-1 receptor agonists are safe and effective in modestly reducing weight, BMI, glycated hemoglobin A1c, and systolic blood pressure in children and adolescents with obesity in a clinical setting, albeit with increased rates of nausea. PROSPERO ID CRD42020195869.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jpeds.2021.05.009

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 27

  1. Di Cesare, 2019, The epidemiological burden of obesity in childhood: a worldwide epidemic requiring urgent action, BMC Med, 17, 212, 10.1186/s12916-019-1449-8 · DOI · Paper page
  2. Gori, 2017, Effectiveness of educational and lifestyle interventions to prevent paediatric obesity: systematic review and meta-analyses of randomized and non-randomized controlled trials, Obes Sci Pract, 3, 235, 10.1002/osp4.111 · DOI
  3. Cardel, 2020, Obesity treatment among adolescents: a review of current evidence and future directions, JAMA Pediatr, 174, 609, 10.1001/jamapediatrics.2020.0085 · DOI · Paper page
  4. Mead, 2016, Drug interventions for the treatment of obesity in children and adolescents, Cochrane Database Syst Rev, 11, CD012436
  5. Ryan, 2017, Recombinant incretin-secreting microbe improves metabolic dysfunction in high-fat diet fed rodents, Sci Rep, 7, 13523, 10.1038/s41598-017-14010-x · DOI
  6. Cole, 2000, Establishing a standard definition for child overweight and obesity worldwide: international survey, BMJ (Clinical research ed), 320, 1240, 10.1136/bmj.320.7244.1240 · DOI · Paper page
  7. Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration, BMJ (Clinical research ed), 339, b2700, 10.1136/bmj.b2700 · DOI · Paper page
  8. Booth, 2012, The nuts and bolts of PROSPERO: an international prospective register of systematic reviews, Syst Rev, 1, 2, 10.1186/2046-4053-1-2 · DOI · Paper page
  9. Mastrandrea, 2019, Liraglutide effects in a paediatric (7-11 y) population with obesity: a randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics, Pediatr Obes, 14, e12495, 10.1111/ijpo.12495 · DOI · Paper page
  10. Kelly, 2013, The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial, JAMA Pediatr, 167, 355, 10.1001/jamapediatrics.2013.1045 · DOI · Paper page
  11. Kelly, 2012, Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study, Obesity (Silver Spring), 20, 364, 10.1038/oby.2011.337 · DOI · Paper page
  12. Danne, 2017, Liraglutide in an Adolescent population with obesity: a randomized, double-blind, placebo-controlled 5-week trial to assess safety, tolerability, and pharmacokinetics of liraglutide in adolescents aged 12-17 years, J Pediatr, 181, 146, 10.1016/j.jpeds.2016.10.076 · DOI · Paper page
  13. Weghuber, 2020, A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity, Pediatr Obes, 15, e12624, 10.1111/ijpo.12624 · DOI · Paper page
  14. Zhou, 2017, The effects of GLP-1 analogues on pre-diabetes of the children, Exp Ther Med, 13, 1426, 10.3892/etm.2017.4129 · DOI
  15. Klein, 2014, Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial, Diabetes Technol Ther, 16, 679, 10.1089/dia.2013.0366 · DOI · Paper page
  16. Tamborlane, 2019, Liraglutide in children and adolescents with type 2 diabetes, N Engl J Med, 381, 637, 10.1056/NEJMoa1903822 · DOI · Paper page
  17. Buse, 2013, Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study, Lancet, 381, 117, 10.1016/S0140-6736(12)61267-7 · DOI · Paper page
  18. Petroni, 2019, Combination of GLP-1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: a retrospective cohort study, Endocrinol Diabetes Metab, 2, e00082, 10.1002/edm2.82 · DOI
  19. Gerstein, 2019, Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial, Lancet, 394, 121, 10.1016/S0140-6736(19)31149-3 · DOI · Paper page
  20. Husain, 2019, Oral semaglutide and cardiovascular outcomes in patients with type 2 Diabetes, N Engl J Med, 381, 841, 10.1056/NEJMoa1901118 · DOI · Paper page
  21. Hasegawa, 2018, Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins, J Clin Lipidol, 12, 62, 10.1016/j.jacl.2017.11.006 · DOI
  22. Boniol, 2018, Incretin-based therapies and the short-term risk of pancreatic cancer: results from two retrospective cohort studies, Diabetes Care, 41, 286, 10.2337/dc17-0280 · DOI · Paper page
  23. Pinto, 2019, Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis, Sci Rep, 9, 2375, 10.1038/s41598-019-38956-2 · DOI · Paper page
  24. Li, 2020, Improving adherence to weight-loss medication (liraglutide 3.0 mg) using mobile phone text messaging and healthcare professional support, Obesity (Silver Spring), 28, 1889, 10.1002/oby.22930 · DOI
  25. Maljaei, 2020, Liraglutide for adolescents with obesity, N Engl J Med, 383, 1193
  26. Anker, 2020, Liraglutide for adolescents with obesity, N Engl J Med, 383, 1192, 10.1056/NEJMc2023284 · DOI
  27. Dube, 2020, Effect of liraglutide on food consumption, appetite sensations and eating behaviours in overweight people with type 1 diabetes, Diabetes Obes Metab, 22, 1417, 10.1111/dom.14050 · DOI · Paper page

Cited by

See all 111

Metadata

Authors
Ryan, P. M., Seltzer, S., Hayward, N. E., Rodriguez, D. A., Sless, R. T., & Hawkes, C. P.
Venue
The Journal of Pediatrics
Publisher
Elsevier BV
Published
2021-09
Volume
236
Pages
137-147.e13
ISSN
0022-3476 (ISSN-L)
OpenAlex
W3160819927
Cited by
111
References
15
FWCI
2.62
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis. https://app.cochat.ai/papers/10.1016/j.jpeds.2021.05.009
The paper
Ryan, P. M., Seltzer, S., Hayward, N. E., Rodriguez, D. A., Sless, R. T., & Hawkes, C. P. (2021). Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis. The Journal of Pediatrics. https://doi.org/10.1016/j.jpeds.2021.05.009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.